3-(Methoxymethyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine

Catalog No. :
ACCXKL771
CAS No. :
1174766-05-2
Molecular Formula :
C13H20BNO3
Molecular Weight :
249.12

IUPAC Name:3-(methoxymethyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine

3-(Methoxymethyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
250mg98%$565.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name3-(Methoxymethyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine
IUPAC Name3-(methoxymethyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine
MDL No.MFCD12198144
Molecular FormulaC13H20BNO3
Molecular Weight249.12
SMILESCOCC1=CN=CC(B2OC(C)(C)C(C)(C)O2)=C1
InChI KeyHVUZCEBLLIWKEE-UHFFFAOYSA-N
Synonym3-(MethoxyMethyl)-5-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)pyridine;Pyridine, 3-(methoxymethyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-
CAS No.1174766-05-2

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P312-P330-P362-P403+P233-P501

Synthetic Route by SureRoute

1. ACCXKL771 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACTOBU801 route compound structure diagram
    ACTOBU80173183-34-3 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACCXKL771 route product structure diagram
    ACCXKL7711174766-05-2
Inquiry

2. ACCXKL771 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACQVKH312 route compound structure diagram
    ACQVKH3121184-54-9 In Stock
  4. Then
  5. ACCXKL771 route product structure diagram
    ACCXKL7711174766-05-2
Inquiry

Comments (0)